RCKT Q4 2023 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$63M

Net Income

-$60M

EPS (Diluted)

$-0.64

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$34M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$566M

Total Liabilities

$74M

Stockholders' Equity

$493M

Cash & Equivalents

$56M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$63M	-$69M	+8.4%
Net Income	-$60M	-$67M	+10.6%